Researchers have developed an AI model that can predict where a drug molecule can be chemically altered.
PlaqueTec recruits first ten patients in BIOPATTERN trial
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and